Your browser is no longer supported. Please, upgrade your browser.
ZGNX Zogenix, Inc. daily Stock Chart
ZGNX [NASD]
Zogenix, Inc.
Index- P/E- EPS (ttm)-9.43 Insider Own0.20% Shs Outstand48.19M Perf Week-1.49%
Market Cap1.59B Forward P/E- EPS next Y-2.19 Insider Trans-34.68% Shs Float51.37M Perf Month1.60%
Income-410.10M PEG- EPS next Q-0.96 Inst Own90.44% Short Float12.22% Perf Quarter16.15%
Sales4.90M P/S324.47 EPS this Y-198.20% Inst Trans19.47% Short Ratio6.62 Perf Half Y-38.60%
Book/sh9.35 P/B3.12 EPS next Y45.80% ROA-80.20% Target Price- Perf Year-21.88%
Cash/sh7.70 P/C3.78 EPS next 5Y8.80% ROE-116.20% 52W Range16.65 - 57.22 Perf YTD-44.12%
Dividend- P/FCF- EPS past 5Y-37.00% ROI-175.40% 52W High-49.09% Beta1.81
Dividend %- Quick Ratio5.40 Sales past 5Y-33.90% Gross Margin- 52W Low74.95% ATR1.63
Employees141 Current Ratio5.40 Sales Q/Q- Oper. Margin- RSI (14)56.41 Volatility5.43% 5.81%
OptionableYes Debt/Eq0.00 EPS Q/Q35.80% Profit Margin- Rel Volume0.69 Prev Close29.00
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume948.32K Price29.13
Recom1.80 SMA204.36% SMA5012.69% SMA200-25.00% Volume654,430 Change0.45%
Mar-06-20Initiated Citigroup Neutral $27
Feb-07-20Reiterated Needham Buy $58 → $54
Feb-07-20Downgrade Ladenburg Thalmann Buy → Neutral $35
Oct-21-19Initiated Needham Buy $58
Jun-27-19Upgrade Guggenheim Neutral → Buy $40 → $64
Apr-09-19Downgrade Guggenheim Buy → Neutral
Nov-05-18Initiated Piper Jaffray Overweight
Sep-14-18Initiated BofA/Merrill Buy $63
Sep-12-18Initiated Northland Capital Outperform $70
Sep-07-18Initiated B. Riley FBR Buy $116
Aug-23-18Initiated Ladenburg Thalmann Buy $71
Aug-15-18Resumed Stifel Buy $65 → $69
Jul-13-18Reiterated Stifel Buy $55 → $65
Nov-27-17Initiated JMP Securities Mkt Outperform
Oct-03-17Reiterated Mizuho Buy $28 → $51
Sep-29-17Upgrade William Blair Mkt Perform → Outperform
Oct-04-16Resumed Leerink Partners Outperform $17
Aug-11-15Reiterated Oppenheimer Outperform $20 → $23
Jul-15-15Reiterated Brean Capital Buy $20 → $28
Apr-22-15Initiated Piper Jaffray Overweight $2.50
May-28-20 11:24AM  Introducing Zogenix (NASDAQ:ZGNX), The Stock That Zoomed 134% In The Last Three Years Simply Wall St.
May-27-20 09:37PM  Edited Transcript of ZGNX earnings conference call or presentation 5-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-15-20 08:00AM  Zogenix Launches Shine Forward with Dravet, a New Source of Inspiring Ideas for Parents of Children Living with Dravet Syndrome GlobeNewswire
May-06-20 06:00PM  Zogenix Inc (ZGNX) Q1 2020 Earnings Call Transcript Motley Fool
08:00AM  Zogenix to Participate in the BofA Securities 2020 Virtual Healthcare Conference GlobeNewswire
May-05-20 07:05PM  Zogenix (ZGNX) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:01PM  Zogenix Provides Corporate Update and Reports First Quarter 2020 Financial Results GlobeNewswire
May-04-20 08:55AM  Is a Surprise Coming for Zogenix (ZGNX) This Earnings Season? Zacks
Apr-28-20 12:56PM  Zogenix, Inc.'s (NASDAQ:ZGNX) Path To Profitability Simply Wall St. -6.20%
08:00AM  Zogenix to Release First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 5 GlobeNewswire
Apr-20-20 08:00AM  Zogenix Appoints Shawnte Mitchell as Executive Vice President, General Counsel & Secretary GlobeNewswire
Apr-16-20 09:46AM  How Zogenix (ZGNX) Stock Stands Out in a Strong Industry Zacks
Apr-15-20 08:00AM  Zogenix to Host Investor Conference Call and Webcast on Two Studies Evaluating FINTEPLA® in Dravet Syndrome and Sunflower Syndrome GlobeNewswire
Apr-07-20 02:16PM  Edited Transcript of ZGNX earnings conference call or presentation 7-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-29-20 12:31PM  Is Zogenix, Inc. (ZGNX) Going to Burn These Hedge Funds? Insider Monkey
Mar-24-20 07:52AM  Edited Transcript of ZGNX earnings conference call or presentation 2-Mar-20 9:30pm GMT Thomson Reuters StreetEvents +12.96%
Mar-21-20 09:08AM  Co-founder & Chairman Cam Garner Just Bought Shares In Zogenix, Inc. (NASDAQ:ZGNX) Simply Wall St.
Mar-06-20 04:05PM  Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire -8.04%
Mar-05-20 11:09AM  3 Top Biotech Stocks With Major Catalysts Approaching TipRanks
Mar-03-20 09:05PM  Zogenix Prices Public Offering of Common Stock GlobeNewswire
05:07PM  Zogenix Announces Proposed Public Offering of Common Stock GlobeNewswire
Mar-02-20 04:01PM  Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results GlobeNewswire
Feb-28-20 07:28AM  The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO Benzinga +5.87%
Feb-27-20 04:27PM  Biotech Stock Crumbles To Three-Year Low On Delayed Seizure Drug Investor's Business Daily -9.09%
08:00AM  Zogenix Announces FDA Extension of Review Period for FINTEPLA® in Dravet Syndrome GlobeNewswire
Feb-24-20 08:00AM  Zogenix to Release Fourth Quarter and Full-Year 2019 Financial Results and Host Conference Call and Webcast on March 2 GlobeNewswire
Feb-11-20 11:27AM  3 Beaten-Down Biotech Stocks With +50% Upside Potential TipRanks
Feb-07-20 04:14PM  This Biotech Cratered On Its Good But Not Good Enough Test Results Investor's Business Daily -38.96%
07:32AM  The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns Benzinga
Feb-06-20 04:01PM  Zogenix Announces Positive Top-line Results from Global Pivotal Phase 3 Trial of FINTEPLA® for the Treatment of Lennox-Gastaut Syndrome GlobeNewswire
Jan-23-20 12:18PM  We're Not Very Worried About Zogenix's (NASDAQ:ZGNX) Cash Burn Rate Simply Wall St.
Dec-26-19 11:53AM  Hedge Fund Favorites vs. Zogenix, Inc. (ZGNX) In 2019 Insider Monkey
Dec-17-19 07:04PM  The Lancet Publishes Phase 3 Trial Results for Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome GlobeNewswire +5.58%
Dec-05-19 08:15AM  Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2019 Annual Meeting GlobeNewswire
Dec-04-19 12:42PM  Heres What Hedge Funds Think About Zogenix, Inc. (ZGNX) Insider Monkey
Dec-02-19 04:01PM  JAMA Neurology Publishes Phase 3 Study of Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug Regimens GlobeNewswire
08:00AM  Zogenix to Present New Data for Its Investigational Drug FINTEPLA® at the American Epilepsy Society Annual Meeting GlobeNewswire
Nov-27-19 08:00AM  Zogenix to Participate in the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-25-19 09:13AM  Investors Who Bought Zogenix (NASDAQ:ZGNX) Shares Five Years Ago Are Now Up 411% Simply Wall St.
08:00AM  Zogenix Announces FDA Acceptance for Filing of New Drug Application and Priority Review for FINTEPLA® for the Treatment of Dravet Syndrome GlobeNewswire
Nov-21-19 02:42PM  Shareholder Alert: Robbins LLP Reminds Investors Zogenix, Inc. (ZGNX) Sued for Misleading Shareholders Business Wire
Nov-18-19 04:43PM  Ties to Bay Area drug companies could help (or not) this latest presidential hopeful American City Business Journals
Nov-12-19 08:00AM  Zogenix to Present at Two Investor Conferences in November GlobeNewswire
Nov-07-19 07:35PM  Zogenix (ZGNX) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:01PM  Zogenix Provides Corporate Update and Reports Third Quarter 2019 Financial Results GlobeNewswire
Oct-31-19 08:00AM  Zogenix to Release Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7 GlobeNewswire
Oct-25-19 09:00AM  Zogenix Announces New Positive Data for Its Investigational Drug FINTEPLA® in Dravet Syndrome GlobeNewswire
Oct-21-19 10:02AM  Is Zogenix, Inc. (ZGNX) A Good Stock To Buy? Insider Monkey
08:00AM  Zogenix Announces Presentation of New Data for FINTEPLA® for the Treatment of Dravet Syndrome at the Child Neurology Society Annual Meeting GlobeNewswire
Oct-11-19 01:33PM  Does The Zogenix, Inc. (NASDAQ:ZGNX) Share Price Fall With The Market? Simply Wall St.
Oct-08-19 08:28PM  Bragar Eagel & Squire is Investigating Certain Officers and Directors of CBL & Associates Properties, EQT Corporation, and Zogenix and Encourages Investors to Contact the Firm GlobeNewswire
Oct-07-19 08:00AM  Zogenix Presents Positive Clinical Study Results for Investigational Treatment for TK2 Deficiency GlobeNewswire
Sep-26-19 07:00AM  Zogenix Resubmits New Drug Application for FINTEPLA® for the Treatment of Dravet Syndrome to U.S. Food and Drug Administration GlobeNewswire
Sep-23-19 05:23PM  ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses to Contact the Firm GlobeNewswire
Sep-18-19 08:49PM  Bragar Eagel & Squire is Investigating Certain Officers and Directors of Orion Group Holdings, Zogenix, and Apyx and Encourages Investors to Contact the Firm GlobeNewswire
Sep-16-19 05:10PM  ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Sep-11-19 09:00PM  IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE +5.38%
Sep-09-19 07:20PM  INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
08:00AM  Zogenix Completes Acquisition of Modis Therapeutics, Inc. GlobeNewswire
Sep-07-19 02:59PM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Sep-06-19 03:38PM  Why Shares of Drugmaker Zogenix Dropped 11.4% in August Motley Fool
Sep-04-19 09:04PM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Sep-03-19 02:49PM  INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
02:00PM  IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Aug-30-19 10:59AM  Edited Transcript of ZGNX earnings conference call or presentation 6-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-29-19 10:19AM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
Aug-26-19 04:36PM  Why Overstock.com, Zogenix, and Mogu Slumped Today Motley Fool -8.44%
04:09PM  Why Zogenix Stock Sank Today Motley Fool
09:03AM  Zogenix Drops After Acquiring Modis Therapeutics TheStreet.com
08:12AM  Zogenix Will Acquire Modis Therapeutics In $250M Deal Benzinga
07:00AM  Zogenix Announces Acquisition of Modis Therapeutics, Inc. GlobeNewswire
Aug-22-19 08:36AM  A Holistic Look At Zogenix, Inc. (NASDAQ:ZGNX) Simply Wall St.
Aug-12-19 07:15PM  Zogenix Inc (ZGNX) EVP, CFO, Treasurer & Sec. Michael P Smith Sold $750,000 of Shares GuruFocus.com
Aug-06-19 10:24PM  Zogenix Inc (ZGNX) Q2 2019 Earnings Call Transcript Motley Fool
Jul-31-19 01:48PM  Steven Cohen Charges Into Chiasma GuruFocus.com
Jul-30-19 08:00AM  Zogenix to Release Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 6 GlobeNewswire
Jul-29-19 08:33PM  How this East Bay biotech moved from an 'error' to a potential treatment for kids with severe seizures American City Business Journals
Jul-17-19 06:58AM  Is Zogenix, Inc. (NASDAQ:ZGNX) A Financially Strong Company? Simply Wall St.
Jul-08-19 06:29PM  Here's Why Zogenix Leaped 26.8% in June Motley Fool
08:00AM  Zogenix Completes Enrollment in Phase 3 Trial of FINTEPLA® in Lennox-Gastaut Syndrome GlobeNewswire
Jul-07-19 07:45AM  3 Hot Biotechs Trending Now TipRanks
Jul-05-19 10:15PM  Zogenix Inc (ZGNX) President and CEO Stephen J Farr Sold $1.6 million of Shares GuruFocus.com
Jun-27-19 05:12PM  Can This Biotech Stock Rival The First FDA-Approved Cannabis Medicine? Investor's Business Daily +20.91%
12:17PM  Here's Why Zogenix Shares Rose as Much as 23.8% Today Motley Fool
10:13AM  Zogenix Secures FDA Approval For Resubmission Of Seizure Drug Application Benzinga
08:00AM  Zogenix Announces FDA Agreement to Proceed with Resubmission of FINTEPLA® NDA GlobeNewswire
Jun-17-19 09:56AM  Zogenix, Inc.'s (NASDAQ:ZGNX) Shift From Loss To Profit Simply Wall St.
Jun-14-19 08:31AM  Hedge Funds Have Never Been More Bullish On Zogenix, Inc. (ZGNX) Insider Monkey
Jun-11-19 03:10PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of EB, BE and ZGNX ACCESSWIRE
02:42PM  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zogenix, Inc. GlobeNewswire
11:05AM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ZGNX, XENT and CYH ACCESSWIRE
10:30AM  ZGNX, BV & TRNX - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Deadlines ACCESSWIRE
Jun-10-19 10:15PM  CLASS ACTION UPDATE for ZGNX, BSX and JMIA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
05:20PM  FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
05:00PM  Rosen, A Globally Recognized Law Firm: June 11 Deadline in Zogenix, Inc. in Securities Class Action - ZGNX ACCESSWIRE
Jun-08-19 02:34PM  FINAL DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
Jun-07-19 07:00PM  SHAREHOLDER ALERT: ZGNX LYFT SCOR: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
06:35PM  IMPORTANT DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
03:35PM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of WSR, ZGNX and XENT ACCESSWIRE
03:00PM  Zogenix, Inc. (ZGNX), BrightView Holdings, Inc. (BV) & Taronis Technologies, Inc. f/k/a MagneGas Applied Technology (TRNX) - Bronstein, Gewirtz & Grossman, LLC Notifies of Class Actions GlobeNewswire
Zogenix, Inc., a pharmaceutical company, develops and commercializes transformative therapies to enhance the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome (LGS); and which is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It also developing MT1621, an investigational deoxynucleoside substrate enhancement therapy for the treatment of inherited mitochondrial DNA depletion disorder thymidine kinase 2 deficiency (TK2d). The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Farfel Gail MEVP/Chief Development OfficerMay 12Sale28.212,57372,5845,048May 13 05:39 PM
Sagrolikar Ashish MEVP & CHIEF COMMERCIAL OFFICERMay 08Buy25.451,00025,4505,913May 11 06:18 PM
WIGGINS MARK CDirectorMar 23Buy20.482,50051,1962,500Mar 24 04:38 PM
FARR STEPHEN JPresident and CEOMar 19Option Exercise10.359,66199,99165,251Mar 20 04:01 PM
FARR STEPHEN JPresident and CEOMar 19Sale18.516,158113,96455,590Mar 20 04:01 PM
Galer Bradley S.EVP/Chief Medical OfficerMar 18Buy19.691,00019,68510,015Mar 20 04:01 PM
FARR STEPHEN JPresident and CEOMar 15Option Exercise0.0010,000064,228Mar 17 07:25 PM
Galer Bradley S.EVP/Chief Medical OfficerMar 15Option Exercise0.003,59509,573Mar 17 07:25 PM
Sagrolikar Ashish MEVP & CHIEF COMMERCIAL OFFICERMar 15Option Exercise0.002,03205,517Mar 17 07:25 PM
Smith Michael PEVP, CFO, Treasurer & Sec.Mar 15Option Exercise0.003,59504,207Mar 17 07:24 PM
Farfel Gail MEVP/Chief Development OfficerMar 15Option Exercise0.003,65708,317Mar 17 07:24 PM
GARNER CAM LDirectorMar 13Buy21.838,000174,6478,000Mar 18 05:48 PM
FARR STEPHEN JPresident and CEOJan 08Option Exercise10.3934,225355,58290,933Jan 10 04:15 PM
FARR STEPHEN JPresident and CEOJan 08Sale51.8934,2251,775,92156,708Jan 10 04:15 PM
Smith Michael PEVP, CFO, Treasurer & Sec.Jan 02Option Exercise10.3522,500232,87523,887Jan 03 04:13 PM
Smith Michael PEVP, CFO, Treasurer & Sec.Jan 02Sale51.7922,5001,165,3401,387Jan 03 04:13 PM
BREITMEYER JAMES BDirectorDec 16Option Exercise8.995,00044,9506,250Dec 18 04:07 PM
BREITMEYER JAMES BDirectorDec 16Sale50.005,000250,0001,250Dec 18 04:07 PM
BREITMEYER JAMES BDirectorNov 25Option Exercise8.995,00044,9506,250Nov 27 04:13 PM
FARR STEPHEN JPresident and CEONov 25Option Exercise10.3534,225354,22990,752Nov 27 04:14 PM
Smith Michael PEVP, CFO, Treasurer & Sec.Nov 25Option Exercise10.3515,000155,25016,387Nov 27 04:14 PM
Smith Michael PEVP, CFO, Treasurer & Sec.Nov 25Sale48.0015,000720,0001,387Nov 27 04:14 PM
FARR STEPHEN JPresident and CEONov 25Sale50.0034,2251,711,25056,527Nov 27 04:14 PM
BREITMEYER JAMES BDirectorNov 25Sale50.005,000250,0001,250Nov 27 04:13 PM
FARR STEPHEN JPresident and CEOAug 29Option Exercise20.005,000100,00060,158Aug 30 04:10 PM
Farfel Gail MEVP/Chief Development OfficerAug 22Sale52.003,446179,1924,891Aug 23 04:09 PM
Smith Michael PEVP, CFO, Treasurer & Sec.Aug 09Option Exercise10.3515,000155,25016,387Aug 12 05:51 PM
WIGGINS MARK CDirectorAug 09Option Exercise15.046,25094,0006,250Aug 12 05:51 PM
Smith Michael PEVP, CFO, Treasurer & Sec.Aug 09Sale50.0015,000750,0001,387Aug 12 05:51 PM
WIGGINS MARK CDirectorAug 09Sale50.006,250312,5000Aug 12 05:51 PM
FARR STEPHEN JPresident and CEOJul 03Option Exercise16.1734,225553,58889,383Jul 05 07:12 PM
FARR STEPHEN JPresident and CEOJul 03Sale48.0134,2251,643,16155,158Jul 05 07:12 PM
Smith Michael PEVP, CFO, Treasurer & Sec.Jun 27Option Exercise10.3515,000155,25016,387Jul 01 08:43 PM
Smith Michael PEVP, CFO, Treasurer & Sec.Jun 27Sale46.3215,000694,8001,387Jul 01 08:43 PM